Treatment News : Increased Mortality Seen in Women With Kidney Disease Despite HIV Treatment

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » July 2010

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

July 8, 2010

Increased Mortality Seen in Women With Kidney Disease Despite HIV Treatment

Women with chronic kidney disease (CKD) who start antiretroviral (ARV) therapy have a two-fold increased risk of mortality compared with HIV-positive women who don’t have CKD, according to a study published online July 6 in the Journal of Acquired Immune Deficiency Syndromes.

CKD is associated with an increased risk of premature death in the general population, often from cardiovascular disease. Contributing factors to CKD include hepatitis C infection, diabetes and high blood pressure. An older study in HIV-positive women found that those with CKD have a higher mortality risk, but the study did not explore whether ARV therapy might diminish that risk.
    
To explore the impact of ARVs on mortality, Michelle Estrella, MD, MHS, from Johns Hopkins School of Medicine in Baltimore and her colleagues analyzed data from the Women’s Interagency HIV Study (WIHS). Their analysis included 1,415 HIV-positive women, of whom 44 had CKD at the time they started ARV therapy. In general, women with CKD were likely to be older, have had lower pretreatment CD4s and to have diabetes and high blood pressure than women without CKD.

Estrella and her colleagues found that women with CKD overall were more than twice as likely to die prematurely after starting ARVs than women without CKD. When Estrella’s team factored in diabetes and hypertension, the risk diminished slightly, to just under two-fold. The authors found that reductions in the estimated glomerular filtration rate (eGFR)—a common test of kidney function—also predicted an increased mortality risk in women with CKD. After accounting for diabetes and hypertension, however, the increased risk was seen only in women with a previous AIDS diagnosis.

“Our study underscores the importance of early screening for kidney disease in HIV-infected women before [ARV therapy] initiation,” the authors conclude.

Search: Chronic kidney disease, eGFR, estimated glomerular filtration rate, Michelle Estrella, Women's Interagency HIV Study, WIHS, mortality


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    Drew949
    South Orange County
    California


    koffeeboss
    Tucson
    Arizona


    Fred9774
    Brooklyn
    New York


    kmfdm221
    Arcata
    California
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Do you work with your doc to design your own treatment regimen?
Yes
No

Survey
PrEP Course

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.